My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 609

    1.

    Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

    Ortonne JP, Shear N, Shumack S, Henninger E; CLEAR Multinational Study Group.

    BMC Dermatol. 2005 Dec 16;5:13.PMID: 16359548 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr.

    J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38.PMID: 14964744 [PubMed - indexed for MEDLINE]Related articles

    3.

    CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

    Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group.

    Br J Dermatol. 2006 Jul;155(1):170-81.PMID: 16792770 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group.

    JAMA. 2003 Dec 17;290(23):3073-80. Erratum in: JAMA. 2004 Mar 3;291(9):1070. PMID: 14679270 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

    Arch Dermatol. 2005 Jan;141(1):31-8.PMID: 15655139 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

    Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.PMID: 17083854 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

    Dermatology. 2008;216(3):260-70. Epub 2008 Jan 11.PMID: 18187944 [PubMed - indexed for MEDLINE]Related articles

    8.

    Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.

    Br J Dermatol. 2008 Mar;158(3):549-57. Epub 2007 Nov 28.PMID: 18047521 [PubMed - indexed for MEDLINE]Related articles

    9.

    Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.

    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA.

    Health Qual Life Outcomes. 2003 Oct 8;1:53.PMID: 14613569 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

    Br J Dermatol. 2005 Dec;153(6):1192-9.PMID: 16307657 [PubMed - indexed for MEDLINE]Related articles

    11.

    Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.

    Health Qual Life Outcomes. 2008 Oct 2;6:75.PMID: 18831744 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.

    J Dermatolog Treat. 2007;18(1):25-31.PMID: 17365264 [PubMed - indexed for MEDLINE]Related articles

    13.

    Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.

    Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; Efalizumab Study Group.

    Int J Dermatol. 2006 May;45(5):605-14.PMID: 16700803 [PubMed - indexed for MEDLINE]Related articles

    14.

    Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

    J Dermatolog Treat. 2007;18(6):341-50.PMID: 18058494 [PubMed - indexed for MEDLINE]Related articles

    15.

    Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

    Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA.

    Drug Saf. 2008;31(8):715-26.PMID: 18636790 [PubMed - indexed for MEDLINE]Related articles

    16.

    Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

    Br J Dermatol. 2006 Jun;154(6):1161-8.PMID: 16704649 [PubMed - indexed for MEDLINE]Related articles

    17.

    Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

    Br J Dermatol. 2005 May;152(5):954-60.PMID: 15888152 [PubMed - indexed for MEDLINE]Related articles

    18.

    The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

    Health Qual Life Outcomes. 2006 Sep 27;4:71.PMID: 17005043 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.

    Katugampola RP, Lewis VJ, Finlay AY.

    Br J Dermatol. 2007 May;156(5):945-50. Epub 2007 Mar 28. Review.PMID: 17388922 [PubMed - indexed for MEDLINE]Related articles

    20.

    Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

    Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group.

    J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33.PMID: 15761420 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity